Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05292859 · ClinicalTrials.gov registry record
Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
A clinical trial, sponsored by Alaunos Therapeutics.
- Completed
- Registry status
- 7
- Enrollment target
NCT05292859 is a clinical trial that has completed, run by Alaunos Therapeutics. The registered enrollment target is 7 participants.
The verdict
NCT05292859 has completed, sponsored by Alaunos Therapeutics.
- COMPLETED
- Registry status
- 7 participants
- Enrollment target
Study Summary
Long-Term Follow-Up Study for Subjects Enrolled in the Phase I/II Study of Autologous T Cells Engineered using the Sleeping Beauty System to Express T cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects with Solid Tumors
Interventions
- BIOLOGICAL Neoantigen specific TCR-T cell drug product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2025-05-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05292859
The ClinicalTrials.gov registry entry for NCT05292859 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alaunos Therapeutics, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Neoantigen specific TCR-T cell drug product is the first listed.
NCT05292859 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05292859 about?
NCT05292859 is a clinical study titled "Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs". Long-Term Follow-Up Study for Subjects Enrolled in the Phase I/II Study of Autologous T Cells Engineered using the Sleeping Beauty System to Express T cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects with Solid Tumors
What is the current status of trial NCT05292859?
This trial is currently completed. The enrollment target is 7 participants. The study started on 2023-03-01. Estimated completion is 2025-05-30.
What interventions are being tested in trial NCT05292859?
The interventions under investigation include: Neoantigen specific TCR-T cell drug product (BIOLOGICAL).
Who is sponsoring clinical trial NCT05292859?
This trial is sponsored by Alaunos Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.